Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age
- PMID: 30554024
- PMCID: PMC6348117
- DOI: 10.1016/j.earlhumdev.2018.10.010
Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age
Abstract
Background: While use of prescription opioids and medication assisted therapy (MAT) for opioid use disorder in pregnancy, as well as the incidence of neonatal opioid withdrawal syndrome (NOWS) continue to rise, little is known about outcomes for children with NOWS beyond the newborn period.
Methods: We examined 1) prenatal MAT exposure vs. unexposed healthy controls [HC]; and 2) treatment for NOWS and NOWS severity on infant neurodevelopmental and behavioral outcomes at 5-8 months of age in 78 maternal-infant pairs from the ENRICH prospective cohort study. Data were obtained from 3 study visits: prenatal, delivery, and neurodevelopmental evaluation at 5-8 months of age. Neurodevelopmental outcomes included the Bayley Scales of Infant Development [BSID-III], caregiver questionnaires (Parenting Stress Index [PSI-SF], Infant Behavior Questionnaire [IBQ-R], Sensory Profile), and the experimental Still-Face Paradigm (SFP).
Results: No differences in the BSID-III, PSI-SF, or IBQ-R scores were observed between MAT and HC groups; however, MAT-exposed and HC infants differed with respect to SFP self-regulation (β = -18.9; p = 0.01) and Sensory Profile sensation seeking (OR = 4.87; 95% CI: 1.55; 15.30) after adjusting for covariates. No significant differences between Treated-for-NOWS vs. not-Treated-for-NOWS were observed. Shorter timing to NOWS treatment initiation was associated with higher Total Stress (β = -9.08; p = 0.035), while longer hospitalization was associated with higher Parent-child dysfunctional interaction (p = 0.018) on PSI-SF.
Conclusions: Our results provide additional evidence of little-to-no effect of MAT and pharmacological treatment of NOWS on infant neurodevelopmental and behavioral outcomes at 5-8 months of age. However, prolonged hospitalization might increase family psychosocial stress and requires further examination.
Keywords: Infant neurodevelopment; Medication-assisted treatment; Opioids; Parental stress; Pregnancy; Substance use disorder.
Copyright © 2018 Elsevier B.V. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Illicit Fentanyl in the Prenatal Period: A Significant Emerging Risk for Neonatal Opioid Withdrawal Syndrome.Am J Perinatol. 2025 May;42(7):891-898. doi: 10.1055/a-2437-0828. Epub 2024 Oct 29. Am J Perinatol. 2025. PMID: 39471848
-
Maternal opioid use during pregnancy and the risk of neonatal opioid withdrawal syndrome in the offspring.Acta Obstet Gynecol Scand. 2024 Aug;103(8):1522-1529. doi: 10.1111/aogs.14850. Epub 2024 May 3. Acta Obstet Gynecol Scand. 2024. PMID: 38700023 Free PMC article.
-
Prenatal Use of Medication for Opioid Use Disorder and Other Prescription Opioids in Cases of Neonatal Opioid Withdrawal Syndrome: North Carolina Medicaid, 2016-2018.Am J Public Health. 2021 Sep;111(9):1682-1685. doi: 10.2105/AJPH.2021.306374. Epub 2021 Aug 12. Am J Public Health. 2021. PMID: 34383554 Free PMC article.
-
Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression.Arch Toxicol. 2023 Oct;97(10):2575-2585. doi: 10.1007/s00204-023-03563-8. Epub 2023 Aug 3. Arch Toxicol. 2023. PMID: 37537419 Review.
-
A Practical Approach to Neonatal Opiate Withdrawal Syndrome.Am J Perinatol. 2018 Mar;35(4):324-330. doi: 10.1055/s-0037-1608630. Epub 2017 Nov 3. Am J Perinatol. 2018. PMID: 29100261 Review.
Cited by
-
Neonatal Abstinence Syndrome and Corresponding Pharmacotherapy Approaches from 2 University-affiliated Neonatal Intensive Care Units in Puerto Rico (2018-2020).P R Health Sci J. 2024 Mar;43(1):25-31. P R Health Sci J. 2024. PMID: 38512758 Free PMC article.
-
Systematic Review: Polysubstance Prevalence Estimates Reported during Pregnancy, US, 2009-2020.Matern Child Health J. 2023 Mar;27(3):426-458. doi: 10.1007/s10995-023-03592-w. Epub 2023 Feb 8. Matern Child Health J. 2023. PMID: 36752906 Free PMC article.
-
Post-discharge healthcare utilization in infants with neonatal opioid withdrawal syndrome.Neurotoxicol Teratol. 2021 Jul-Aug;86:106975. doi: 10.1016/j.ntt.2021.106975. Epub 2021 Mar 23. Neurotoxicol Teratol. 2021. PMID: 33766722 Free PMC article.
-
Measurement of emerging neurocognitive and language skills in the HEALthy Brain and Child Development (HBCD) study.Dev Cogn Neurosci. 2024 Dec;70:101461. doi: 10.1016/j.dcn.2024.101461. Epub 2024 Sep 28. Dev Cogn Neurosci. 2024. PMID: 39368284 Free PMC article.
-
Cognitive Outcomes of Young Children After Prenatal Exposure to Medications for Opioid Use Disorder: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Mar 2;3(3):e201195. doi: 10.1001/jamanetworkopen.2020.1195. JAMA Netw Open. 2020. PMID: 32186745 Free PMC article.
References
-
- Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD, Incidence of Neonatal Abstinence Syndrome - 28 States, 1999–2013, MMWR. Morbidity and mortality weekly report. 65 (2016) 799–802. - PubMed
-
- Kaltenbach K, Berghella V, Finnegan L, Opioid dependence during pregnancy. Effects and management, Obstetrics and gynecology clinics of North America. 25 (1998) 139–51. - PubMed
-
- Milliren CE, Gupta M, Graham DA, Melvin P, Jorina M, Ozonoff A, Hospital Variation in Neonatal Abstinence Syndrome Incidence, Treatment Modalities, Resource Use, and Costs Across Pediatric Hospitals in the United States, 2013 to 2016, Hospital pediatrics. 8 (2018) 15–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical